February 21, 2017
Company-funded studies of approved drugs may not catch safety issues
Studies drug companies fund after medicines go on sale may be too small to detect rare side effects, a recent German study suggests.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 21, 2017
Inova to use Omnicell’s Performance Center
Omnicell has bagged a deal with Inova, a not-for-profit healthcare system based in Northern Virginia, for its integrated software and services offering, Performance Center.
February 21, 2017
The thirteenth director; American Brain Tumor Association gets 4 new board members
The American Brain Tumor Association (ABTA) has elected four new members to its Board of Directors in January, to bring the number of directors to thirteen.
February 21, 2017
Sobi, Valeant sign new agreement for UCDs drug distribution
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Ireland’s Valeant Pharmaceuticals for the distribution of Ammonul injection, an acute Urea Cycle Disorders (UCDs) drug, in Europe, the Middle East and North Africa.
February 21, 2017
$100 million for Global HOPE to treat children with cancer and blood disorders, training for 4,800 healthcare pros in Africa
Botswana will be a centert for southern and east Africa for hematology-oncology treatment, as it will get a new $100…
February 21, 2017
Nicox presents positive preclinical results for its eye drug
Nicox, the international ophthalmic R&D company has presented preclinical results from its novel nitric oxide (NO) donating compound, NCX 667 at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy.
February 21, 2017
Neovacs’s lupus and dermatomyositis vaccine to sell in China
Neovacs has signed with BioSense Global a commercial license option agreement for its IFNalpha Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.
February 21, 2017
Abzena expands deal with University College London for making Magacizumab
Abzena has signed a deal with University College London (UCL) to manufacture Magacizumab, an antibody created with its ‘Abzena inside’ Composite Human Antibody technology.
February 21, 2017
Apitope’s multiple sclerosis drug brings brain lesions down
Apitope’s ATX-MS-1467 has reduced the number and volume of brain lesions with a promising safety profile, the company said about results of a test.
February 20, 2017
Russian Government drive to increase domestic manufacturing fuelling growth at CPhI Russia
The partnerships and deals struck at CPhI Russia have helped establish Russia at the forefront of pharmerging markets and it is expected to reach a value of $31.2 billion by 2019.